** Shares of Maryland-based vaccine maker Novavax NVAX.O fall 2.8% to $7.96
** Co says it received a notice on March 7 terminating with immediate effect a purchase agreement with Canada due to missed regulatory approval deadlines for its COVID-19 vaccine
** Co entered into the purchase agreement with Canada in January 2021
** Under the terms of the agreement, $28 million in advanced purchase payments previously received by the company are now refundable to the customer within 30 days of notice
** Up to last close, NVAX had risen 50.% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。